AceLink is advancing a small-molecule treatment option for Fabry disease, which could provide a more convenient alternative ...

AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...

This prospective case-control study included 85 patients with lung involvement related to the COVID-19 virus and a group of ...

Mineralys Therapeutics (MLYS) has completed enrollment in the Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorundrostat for ...